Fasiyal estetik uygulamalarda botulinum toksini

PDF

___

1. American Society of Plastic Surgeons Procedural Statistics. 2000/2004/2005 National Plastic Surghery Statisitcs. www.plasticsurgery. org
2. Erbguth FJ, Naumann M. Historical aspects ofbotulinum toxin: Justinus Kerner (1786-1862) and the ‘sausage poison’. Neurology. 1999, 53: 185-1853.
3. Shantz EJ, Johnson EA. Botulinum toxin: The story of its development for the treatment of human disease. Perspectives in Biology and Medicine. 1997, 40: 317-327.
4. Scott A, Rosenbaum A, Collins C. Pharmacologic weakening of extraocular muscles. Invest. Opthalmol. 1973, 12: 924-927.
5. Scott A. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Opthalmology. 1980, 87: 1044- 1049.
6. Carruthers J, Carruthers J. Treatment of glabellar frown lines with C. Botulinum A exotoxin. J. Derm. Surg. Oncol. 1992, 18: 17-21. 7. Bushara KO, Park DM. Botulinum toxin and sweating. J. Neurol. Neurosurg. Psychiatry. 1994, 57: 1437-1438.
8. Cather JC, Cather JC, Menter A. Update on botulinum toxin for facial aesthetics. Dermatol. Clin. 2002, 20: 749-761.
9. Callaway JE, Arezzo JC, Grethlein AJ. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Semin. Cutan. Med. Surg. 2001, 20: 127-136.
10. Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J. Am. Acad. Dermatol. 2000, 43: 249-259.
11. Klein AW. Complications and adverse reactions with the use of botulinum toxin. Semin. Cutan. Med. Surg. 2001, 20: 109-120.
12. Shimizu T, Sakaguchi G. Production and properties of type F toxin. In Jankavic J, Hallet M, editors. Theraphy with botulinum toxin. New York: Marcel Dekker, 1994, p. 87-92
13. Simpson LL. Molecular pharmocolgy of botulinum toxin and tetanus toxin. Ann. Rev. Pharmacol. Toxicol. 1986, 26: 427-453.
14. Simpson LL. The origin, structure and pharmacological activity of botulinum toxin. Pharmacol. Rev. 1981, 33. 155-188.
15. Binz T, Blasi J, Yamasaki S, et al. Proteolysis of SNAP-25 by types E and A botulinum neurotoxins. J. Biol. Chem. 1994, 269: 1617-1620.
16. Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum – B neurotoxins block transmitter release by proteolytic cleavage of synaptobrevin. Nature. 1992, 359: 832.
17. De Paiva A, Meunier FA, Molgo J, et al. Functional repair of motor end plates afetr botulinum neurotoxin type A poisoning: Biphasic switch of synaptic actvity between nerve sprouts and2 their parent terminals. Proc. Natl. Acad. Sci. USA 96. 1999, 96: 3200-3205.
18. Yavuzer R, Demirtaş Y. Painful injections with Botox. Plast. Reconstr. Surg. 2003, 111: 509.
19. Klein AW. Dilution and storage of botulinum toxin. Dermatol Surg. 1998, 24:1179-80.
20. Garcia A, Fulton JE. Cosmetic denervation of the muscles of facial expression with botulinum toxin. Dermatol. Surg. 1996, 22: 39-43.
21. Tuncer S, Ayhan S, Elmas Ç, et al. Fresh and stored botulinum toxin- A on muscle and nerve ultrastructure: An electron microscopic study. Plast. Reconstre. Surg. 2006, 118 (Suplement)
22. Sami MS, Soparkar CN, Patrinely JR, Hollier LM, Hollier LH. Efficacy of botulinum toxin type A after topical anesthesia. Ophthal. Plast. Reconstr. Surg. 2006, 22:448-452.
23. Carruthers J, Fagien S, Matarasso SL, Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast. Reconstr. Surg. 2004, 114 (Suplement): 1S-22S.
24. Frampton JE, Easthope SE. Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines. Am J Clin Dermatol. 2003, 4: 709-25.
25. Bassichis BA, Thomas JR. The use of Botox to treat glabellar rhytids. Facial Plast Surg Clin North Am. 2003,1: 453-6.
26. Carruthers A, Carruthers J. Botulinum toxin type A for the treatment of glabellar rhytides. Dermatol Clin. 2004, 22:137-44.
27. Chen AH, Frankel AS. Altering brow contour with botulinum toxin. Facial Plast Surg Clin North Am. 2003,11:457-64.
28. Klein AW. Botox for the eyes and eyebrows. Dermatol Clin. 2004, 22:145-9.
29. Carruthers J, Carruthers A. The use of botulinum toxin type A in the upper face. Facial Plast Surg Clin North Am. 2006,14:253-60.
30. Carruthers J, Carruthers A. Botulinum toxin below the eyes. Int Ophthalmol Clin. 2005, 45:133-41.
31. Salti G. Botulinum toxin for periocular lines: the single-injection technique.J. Cosmet. Dermatol. 2004, 3:122-5.
32. Kim DW, Cundiff J, Toriumi DM. Botulinum toxin A for the treatment of lateral periorbital rhytids. Facial Plast Surg Clin North Am. 2003,11:445-51
33. Balikian RV, Zimbler MS. Primary and adjunctive uses of botulinum toxin type A in the periorbital region. Facial Plast Surg Clin North Am. 2005,13:583-90
34. Ghavami A, Janis JE, Guyuron B. Regarding the treatment of dynamic nasal tip ptosis with botulinum toxin A. Plast Reconstr Surg. 2006,118:263-4.
35. Tamura BM, Odo MY, Chang B, Cuce LC, Flynn TC. Treatment of nasal wrinkles with botulinum toxin.Dermatol Surg.2005, 31:271-5.
36. Dayan SH, Kempiners JJ. Treatment of the lower third of the nose and dynamic nasal tip ptosis with Botox. Plast Reconstr Surg. 2005, 115:1784-5.
37. Castro WH, Gomez RS, Da Silva Oliveira J, Moura MD, Gomez RS. Botulinum toxin type A in the management of masseter muscle hypertrophy. J Oral Maxillofac Surg. 2005, 63:20-4.
38. Carruthers J, Carruthers A. Botulinum toxin A in the mid and lower face and neck. Dermatol Clin. 2004, 22:151-8.
39. Kane MA. The functional anatomy of the lower face as it applies to rejuvenation via chemodenervation. Facial Plast Surg. 2005, 21:55- 64.
40. Beer K, Yohn M, Closter J. A double-blinded, placebo-controlled study of Botox for the treatment of subjects with chin rhytids. J Drugs Dermatol. 2005, 4:417-22.
41. Souayah N, Karim H, Kamin SS, McArdle J, Marcus S. Severe botulism after focal injection of botulinum toxin. Neurology. 2006, 67:1855-6.
42. Aristodemou P, Watt L, Baldwin C, Hugkulstone C. Diplopia associated with the cosmetic use of botulinum toxin a for facial rejuvenation. Ophthal Plast Reconstr Surg. 2006, 22:134-6.
43. Sunness JS, Kelman S. Cosmetic botox injection mimicking myasthenia gravis. Plast Reconstr Surg. 2004,113:1515.
44. Wollina U, Konrad H. Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures. Am J Clin Dermatol. 2005, 6:141-50.
45. AJ, Dayan SH. Complications of botulinum toxin A use in facial rejuvenation. Facial Plast Surg Clin North Am. 2003,11:483-92.
46. Klein AW. Contraindications and complications with the use of botulinum toxin. Clin Dermatol. 2004, 22:66-75.
47. Klein AW. Complications with the use of botulinum toxin. Dermatol Clin. 2004, 22:197-205
48. Batra RS, Dover JS, Arndt KA. Adverse event reporting for botulinum toxin type A. J Am Acad Dermatol. 2005, 53:1080-2.
49. de Oliveira Monteiro E. Botulinum toxin and pregnancy. Skinmed. 2006, 5:308.
50. Morgan JC, Iyer SS, Moser ET, Singer C, Sethi KD. Botulinum toxin A during pregnancy: a survey of treating physicians. J Neurol Neurosurg Psychiatry. 2006, 77:117-9.
51. Dayan SH, Bassichis BA. Evaluation of the patient for cosmetic Botox injections. Facial Plast Surg Clin North Am. 2003,11:349-58
52. Beer KR. Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-tosevere glabellar rhytids. Dermatol Surg. 2006, 32:184-97.
53. Maas CS. Botulinum neurotoxins and injectable fillers: minimally invasive management of the aging upper face. Facial Plast Surg Clin North Am. 2006, 14:241-5.
54. Coleman KR, Carruthers J. Combination therapy with BOTOX and fillers: the new rejuvnation paradigm. Dermatol Ther. 2006,19:177- 88.
55. Carruthers J, Carruthers A. Adjunctive botulinum toxin type A: fillers and light-based therapies. Int Ophthalmol Clin. 2005, 45:143- 51.
56. Wise JB, Greco T. Injectable treatments for the aging face. Facial Plast Surg. 2006, 22:140-6.